These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 10063352

  • 1. Mucoactive drugs in the management of chronic obstructive pulmonary disease.
    Del Donno M, Olivieri D.
    Monaldi Arch Chest Dis; 1998 Dec; 53(6):714-9. PubMed ID: 10063352
    [Abstract] [Full Text] [Related]

  • 2. Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs.
    Chest; 1994 Nov; 106(5):1532-7. PubMed ID: 7956415
    [No Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B.
    Novartis Found Symp; 2002 Nov; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
    Crisafulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, Fabbri LM, Bertini M, Clini EM.
    Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
    [Abstract] [Full Text] [Related]

  • 5. Mucoactive agents for airway mucus hypersecretory diseases.
    Rogers DF.
    Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
    [Abstract] [Full Text] [Related]

  • 6. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.
    Vestbo J, Prescott E, Lange P.
    Am J Respir Crit Care Med; 1996 May; 153(5):1530-5. PubMed ID: 8630597
    [Abstract] [Full Text] [Related]

  • 7. Mucoactive drugs and multiple applications in pulmonary disease therapy.
    Hocquigny A, Hugerot H, Ghanem R, Haute T, Laurent V, Cogulet V, Montier T.
    Eur J Pharm Biopharm; 2024 Jan; 194():110-117. PubMed ID: 38048888
    [Abstract] [Full Text] [Related]

  • 8. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.
    Rogers DF.
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):324-32. PubMed ID: 11057087
    [Abstract] [Full Text] [Related]

  • 9. Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease.
    Maestrelli P, Saetta M, Mapp CE, Fabbri LM.
    Am J Respir Crit Care Med; 2001 Nov 15; 164(10 Pt 2):S76-80. PubMed ID: 11734472
    [Abstract] [Full Text] [Related]

  • 10. Mucoactive therapy in COPD.
    Decramer M, Janssens W.
    Eur Respir Rev; 2010 Jun 15; 19(116):134-40. PubMed ID: 20956182
    [Abstract] [Full Text] [Related]

  • 11. Mucoactive drugs.
    Balsamo R, Lanata L, Egan CG.
    Eur Respir Rev; 2010 Jun 15; 19(116):127-33. PubMed ID: 20956181
    [Abstract] [Full Text] [Related]

  • 12. Mucoactive drugs for asthma and COPD: any place in therapy?
    Rogers DF.
    Expert Opin Investig Drugs; 2002 Jan 15; 11(1):15-35. PubMed ID: 11772318
    [Abstract] [Full Text] [Related]

  • 13. Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
    Yan X, Song Y, Shen C, Xu W, Chen L, Zhang J, Liu H, Huang M, Lai G, Qian G, Wang J, Ye X, Zheng J, Bai C.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 15; 12():803-812. PubMed ID: 28405161
    [Abstract] [Full Text] [Related]

  • 14. Mucus hypersecretion in chronic obstructive pulmonary disease.
    Rogers DF.
    Novartis Found Symp; 2001 Jan 15; 234():65-77; discussion 77-83. PubMed ID: 11199104
    [Abstract] [Full Text] [Related]

  • 15. Revisited role for mucus hypersecretion in the pathogenesis of COPD.
    Cerveri I, Brusasco V.
    Eur Respir Rev; 2010 Jun 15; 19(116):109-12. PubMed ID: 20956178
    [Abstract] [Full Text] [Related]

  • 16. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA, Donaldson GC.
    Respir Care; 2003 Dec 15; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation.
    Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM, Higgins IT, Gray RG, Richards SM, Gilliland J, Norman-Smith B.
    Am Rev Respir Dis; 1983 Sep 15; 128(3):491-500. PubMed ID: 6614643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.